In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Online pharmacies will now have to employ stricter checks to stop people who are already a healthy weight or have a history ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones: GLP-1, GIP and glucagon. That appears to have more potent effects on a person's appetite and ...

(Zepbound stimulates, rather than blocks, GIP, while both it and MariTide stimulate a second hormone called GLP-1 that’s become central to obesity treatment.) Helicore claims that, by blocking ...